BACKGROUND AND OBJECTIVES: Oral nutritional supplementation (ONS) was provided to ESRD patients with hypoalbuminemia as part of Fresenius Medical Care Health Plan's (FMCHP) disease management. This study evaluated the association between FMCHP's ONS program and clinical outcomes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Analyses included FMCHP patients with ONS indication (n=470) defined as 2-month mean albumin <3.8 g/dl until reaching a 3-month mean ≥3.8 g/dl from February 1, 2006 to December 31, 2008. Patients did not receive ONS if deemed inappropriate or refused. Patients on ONS were compared with patients who were not, despite meeting ONS indication. Patients with ONS indication regardless of use were compared with Medicare patients with similar serum albumin levels from the 2007 Centers for Medicare and Medicaid Services Clinical Performance Measures Project (CPM). Cox models calculated adjusted hospitalization and mortality risks at 1 year. RESULTS: Among patients with indication for ONS, 276 received supplements and 194 did not. ONS use was associated with 0.058 g/dl higher serum albumin overall (P=0.02); this difference decreased by 0.001 g/dl each month (P=0.05) such that the difference was 0.052 g/dl (P=0.04) in month 6 and the difference was no longer significant in month 12 . In analyses based on ONS use, ONS patients had lower hospitalization at 1 year (68.4%; P<0.01) versus patients without ONS (88.7%), but there was no significant reduction in mortality risk (P=0.29). In analyses based on ONS indication, patients with indication had lower mortality at 1 year (16.2%) compared with CPM patients (23.4%; P<0.01). CONCLUSIONS: These findings suggest that ONS use was associated with significantly lower hospitalization rates but had no significant effect on mortality in a disease management setting.
BACKGROUND AND OBJECTIVES: Oral nutritional supplementation (ONS) was provided to ESRDpatients with hypoalbuminemia as part of Fresenius Medical Care Health Plan's (FMCHP) disease management. This study evaluated the association between FMCHP's ONS program and clinical outcomes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Analyses included FMCHP patients with ONS indication (n=470) defined as 2-month mean albumin <3.8 g/dl until reaching a 3-month mean ≥3.8 g/dl from February 1, 2006 to December 31, 2008. Patients did not receive ONS if deemed inappropriate or refused. Patients on ONS were compared with patients who were not, despite meeting ONS indication. Patients with ONS indication regardless of use were compared with Medicare patients with similar serum albumin levels from the 2007 Centers for Medicare and Medicaid Services Clinical Performance Measures Project (CPM). Cox models calculated adjusted hospitalization and mortality risks at 1 year. RESULTS: Among patients with indication for ONS, 276 received supplements and 194 did not. ONS use was associated with 0.058 g/dl higher serum albumin overall (P=0.02); this difference decreased by 0.001 g/dl each month (P=0.05) such that the difference was 0.052 g/dl (P=0.04) in month 6 and the difference was no longer significant in month 12 . In analyses based on ONS use, ONSpatients had lower hospitalization at 1 year (68.4%; P<0.01) versus patients without ONS (88.7%), but there was no significant reduction in mortality risk (P=0.29). In analyses based on ONS indication, patients with indication had lower mortality at 1 year (16.2%) compared with CPM patients (23.4%; P<0.01). CONCLUSIONS: These findings suggest that ONS use was associated with significantly lower hospitalization rates but had no significant effect on mortality in a disease management setting.
Authors: G Toigo; M Aparicio; P O Attman; N Cano; B Cianciaruso; B Engel; D Fouque; A Heidland; V Teplan; C Wanner Journal: Clin Nutr Date: 2000-08 Impact factor: 7.324
Authors: N V Athienites; D C Miskulin; G Fernandez; S Bunnapradist; G Simon; M Landa; C H Schmid; S Greenfield; A S Levey; K B Meyer Journal: Semin Dial Date: 2000 Sep-Oct Impact factor: 3.455
Authors: Angela Yee-Moon Wang; Ikechi G Okpechi; Feng Ye; Csaba P Kovesdy; Giuliano Brunori; Jerrilynn D Burrowes; Katrina Campbell; Sandrine Damster; Denis Fouque; Allon N Friedman; Giacomo Garibotto; Fitsum Guebre-Egziabher; David Harris; Kunitoshi Iseki; Vivekanand Jha; Kailash Jindal; Kamyar Kalantar-Zadeh; Brandon Kistler; Joel D Kopple; Martin Kuhlmann; Meaghan Lunney; Denise Mafra; Charu Malik; Linda W Moore; S Russ Price; Alison Steiber; Christoph Wanner; Pieter Ter Wee; Adeera Levin; David W Johnson; Aminu K Bello Journal: Clin J Am Soc Nephrol Date: 2022-01-03 Impact factor: 8.237